Effect of furosemide combined with continuous renal replacement therapy on cardiorenal function and inflammatory response in patients with chronic renal and heart failure after hemodialysis.

Purpose: To determine the effect of furosemide combined with continuous renal replacement therapy (CRRT) on cardiorenal function and inflammatory response in patients with chronic renal failure (CRF) and heart failure after hemodialysis. Methods: 130 patients with both CRF and heart failure, who underwent hemodialysis at the Second Hospital Affiliated to Hainan Medical College, China, from October 2020 to October 2022 were recruited as study subjects. They were randomly divided into two groups, with control group administered the Continuous Renal Replacement Therapy (CRRT) while study group received furosemide in addition. The study assessed the clinical outcomes, cardiorenal function and inflammatory factors before and after treatment. Additionally, adverse reactions during treatment were documented for both groups. Results: Study group exhibited a significantly higher (p < 0.001) total response rate compared to control group. Post-treatment, both groups displayed significant increases (p < 0.05) in left ventricular ejection fraction, cardiac output and stroke volume, with study group showing significantly superior results (p < 0.05). Furthermore, post-treatment, both groups experienced significant reductions (p < 0.05) in serum creatinine, blood urea nitrogen, and 24-hour urinary protein levels, with study group displaying significantly lower levels (p < 0.05). Additionally, the interleukin-6, interleukin-1ß and tumor necrosis factor-a levels decreased significantly in both groups post-treatment, with study group exhibiting significantly lower levels (p < 0.05). There was no significant difference in adverse reaction incidence between the two groups. Conclusion: Furosemide combined with CRRT significantly improves cardiorenal function and reduces inflammatory response in patients with CRF and heart failure after hemodialysis. Future research could optimize dosage and administration protocols, explore long-term effects and assess applicability in diverse patient populations. [ABSTRACT FROM AUTHOR]